Our collaboration is an important step for EyeKor in connecting the quality of imaging provided by the ophthalmic photographers with our sponsors, who bring ophthalmic therapeutics into the marketplace to benefit patients suffering from serious ocular diseases.
MADISON, Wis. (PRWEB) November 03, 2017
EyeKor, Inc., announced today that it will collaborate with the Ophthalmic Photographers’ Society (OPS) to develop a Clinical Trial Imaging Certification Program for OPS members who are Certified Retinal Angiographers or Certified Optical Coherence Tomographers. This program aims to accelerate the startup process of pharmaceutical-sponsored ophthalmic clinical trials and provide ongoing support for those trials in terms of the necessary imaging certification requirements.
The use of Certified Clinical Trial Imaging professionals will greatly improve the quality of the specialized imaging required for ophthalmic clinical studies. Specifically, certified imaging professionals will be able to provide a more accurate evaluation of ophthalmic images, thereby enabling earlier evaluation of the data required for the determination of therapeutic success.
EyeKor is a Software-as-a-Service (SaaS) company providing image and data management solutions for ophthalmic clinical trials. As part of the collaboration, certified OPS photographers will use EXCELSIOR™, EyeKor’s 510(k)-cleared, cloud-based software platform, for both clinical and preclinical applications. The software platform will enable pharmaceutical sponsors and their contract research organization (CRO) partners to manage the ocular images and other data collected during their ophthalmic clinical trials and nonclinical studies, enhancing the efficiency and accuracy of data collection and interpretation. EXCELSIOR also allows leading scientists, principal investigators, CRO representatives, data managers, and reading center graders to access and track data in real time.
“We are very pleased to support our ophthalmic photographer partners in this way,” said Christopher J. Murphy, DVM, PhD, DACVO, and CEO of EyeKor. “Our collaboration is an important step for EyeKor in connecting the quality of imaging provided by the ophthalmic photographers with our sponsors, who bring ophthalmic therapeutics into the marketplace to benefit patients suffering from serious ocular diseases. We look forward to continuing our successful relationship.”
Media Inquiries:
Yijun Huang, PhD
Phone: 608-886-3386
Email: yhuang(at)eyekor(dot)com
###
About the Ophthalmic Photographers Society: The Ophthalmic Photographers’ Society is a nonprofit organization dedicated to a highly specialized form of medical photography in the field of ophthalmology. The main objectives of the Society are to provide primary and continuing education in the field of ophthalmic photography, to set and maintain standards for the profession through multiple certification programs, and to promote scientific advancement in ophthalmic imaging technology. Members of the Ophthalmic Photographers' Society perform imaging of all structures of the eye using highly specialized equipment to increase the level of patient care and help to advance the science and practice of ophthalmology.
About EyeKor: EyeKor, Inc., is a Software-as-a-Service (SaaS) company that offers a complete spectrum of integrated ophthalmic clinical trial image data management and analysis services, from preclinical to clinical phases I through IV. EyeKor expertise encompasses a diverse array of ophthalmic testing methods including fundus photography and angiography, optical coherence tomography, fundus autofluorescence imaging, automated visual field testing, and electrophysiological testing. EyeKor’s cloud-based software application, EXCELSIOR™, was built specifically for supporting image data collection and management of ophthalmic preclinical studies and clinical trials. EXCELSIOR™ utilizes the latest web and imaging technologies for data standardization, analysis, grading and reporting. EXCELSIOR™ is cleared with the FDA as a Class II medical device, with specific indication for use for managing ophthalmic clinical trials.